type here...

CATEGORIES

Discover Drugs

LATEST

123Page 2 of 3

TRENDING

EDITORS CHOICE

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Medika Life -
Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

BIO – Biotech Without Borders 

Gil Bashe, Medika Life Editor -
This year’s gathering in Boston—a city long synonymous with health innovation—welcomed more than 20,000 attendees from across the globe. But what stood out most...

Real-World Repercussions of Mislabeling Treatments as Vaccines

Robert Turner, Founding Editor -
Vaccinate, inoculate and immunize are three words that describe the "jab" people get to guard them against serious infectious illnesses. Harmonious - yes - but each offers a different consumer expectation.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories